News

Patients in a precancerous stage of multiple myeloma would be wise to avoid gaining extra weight, according to new research that shows being overweight or obese increases the risk that the condition progresses to cancer. The study, “Obesity and the Transformation of Monoclonal Gammopathy of Underdetermined Significance to Multiple…

The European Commission has granted conditional marketing authorization to Ninlaro (ixazomib) capsules in combination with Revlimid (lenalidomide) and Decadron (dexamethasone) for multiple myeloma patients who have received at least one prior therapy. Ninlaro’s approval was based on results from the TOURNALINE-MM1 Ohase 3 trial and follows a positive opinion issued by…

A combination of nonspecific symptoms, including back pain and weight loss, should alert physicians to the possibility of multiple myeloma. Still, the recognition of symptom patterns is not likely to improve outcomes, as the study did not find any links between the time from first symptoms to diagnosis and survival, making…

The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib) and dexamethasone, for multiple myeloma patients who have received at least one prior therapy. Clinical studies have revealed that adding Darzalex to Revlimid and dexamethasome in myeloma patients with…

Multiple myeloma patients taking the immunomodulatory drug thalidomide may develop a potentially life-threatening dermatologic disorder called toxic epidermal necrolysis (TEN), according to a recent case report published in the International Journal of Dermatology. The study, “Toxic epidermal necrolysis induced by thalidomide and dexamethasone treatment for…

Combining three well-known oral drugs shows potential for heavily pretreated multiple myeloma patients who have grown resistant to therapy with one of the included drugs, according to the results of a study. The trio — low-dose Cytoxan (cyclophosphamide), Revlimid (lenalidomide) and prednisone (also known as Deltasone, among other brands) — was…

Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard two-drug regimen of Revlimid (lenalidomide) and dexamethasone significantly improves health-related quality of life in relapsed multiple myeloma patients, according to a secondary analysis of the ASPIRE clinical trial. These findings, published in the Journal of Clinical Oncology, further support the…

The anti-CD38 agent Darzalex (daratumumab) will be investigated in a Phase 3 clinical trial in combination with Kyprolis (carfilzomib) and Decadron (dexamethasone) in relapsed/refractory multiple myeloma patients. The study will be conducted under a collaboration and supply agreement between Genmab, Janssen Biotech, and Onyx Pharmaceuticals (a subsidiary of…

The U.S. Food and Drug Administration (FDA) has verbally notified BioInvent International that it’s placing a full clinical hold on the company’s Phase 2 trial evaluating BI-505 in multiple myeloma patients. This means Sweden-based BioInvent cannot dose trial patients while the hold is in place. While the company has not…

Karyopharm Therapeutics is set to present novel clinical data on its lead product candidate selinexor, an oral selective inhibitor of nuclear export compound that is being developed for a variety of advanced hematologic and solid tumors. The data, to be presented at the upcoming American Society of Hematology (ASH)…